The Prolaris® Prostate Cancer Prognostic Test delivers actionable results to help radiation oncologists personalize androgen deprivation therapy (ADT) — predicting which patients truly benefit from it and who can safely pursue radiation therapy without hormone therapy for prostate cancer.1
As a radiation oncologist treating men with localized prostate cancer, you face a critical question every day: Does this patient truly benefit from adding androgen deprivation therapy (ADT) to radiation therapy (RT)? Our data shows 1 in 2 men with unfavorable intermediate risk prostate cancer that received the Prolaris Test could avoid ADT.2
The Prolaris Test is the ONLY test that puts ADT benefit in numbers
The Prolaris Test helps you quickly make the most appropriate decision for each patient based on hard data, not assumptions.
The Prolaris Test empowers you to avoid overtreatment and prevent undertreatment — every patient, every plan:
Below the threshold, patients gain no significant benefit from intensifying treatment and can safely pursue single-modality treatment.2-4
Above the threshold, patients benefit from multi-modal treatment:
Hear from radiation oncologist Dr. Fairchild as he discusses why he orders the Prolaris Test on both his favorable and unfavorable intermediate patients.
“For favorable intermediate-risk patients, active surveillance remains an option […] I typically omit hormone therapy based on Prolaris Test results and the risks associated with ADT.”
“The Prolaris Test does in fact, provide a very consistent and double validated model for the multimodal threshold, which helps in a general sense guide who you should routinely consider ADT for or who you should routinely consider omitting it. But at the moment, it’s the only biomarker that provides this highly personal risk estimate of absolute risk reduction so that the individual can really decide, regardless of threshold, whether using or omitting ADT is probably right for them.”
Dr. Jonathan Tward, MD, PhD, FASTRO, Huntsman Cancer Institute at the University of Utah
The Prolaris Test results are designed with patients and providers in mind to quickly help answer pressing clinical questions, improving confidence in selecting the most appropriate management option.
Access detailed ordering instructions, specimen handling guidelines, and pathology resources to streamline every step of the testing process.
Access the official Prolaris Biopsy Test Request Form to streamline orders and ensure complete documentation.
Connect with our team to learn more about integrating the Prolaris Test into your clinical workflow.
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
Contact Information
References:
©2026 Myriad Genetics, Inc. Myriad Genetics, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.